Dr Reddy's gets FDA nod for migraine drug Elyxyb

7 May 2020

Shares of Dr Reddy’s Laboratories (BSE: 500124) rose more than 2% to 3,936.35 rupees, after the Indian drugmaker announced approval of Elyxyb (celecoxib oral solution 25mg/mL) by the US Food and Drug Administration).

Elyxyb (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults. Elyxyb is the latest product emerging from Dr Reddy’s portfolio of successful acute migraine treatments. The company, whose stock is up 32.8% so far this year, is working to commercialize this product through partners.

Celecoxib is the active ingredient of Pfizer’s (NYSE: PFE) off-patent Celebrex brand, for the treatment of osteoarthritis and adult rheumatoid arthritis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK